Drugs / Ceftolozane/tazobactam
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02070757 | Sep 2014 → May 2018 | lung disorder, nosocomial infection | Merck & Co., Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ceftolozane-tazobactam | “Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia” PMID 31563344 ↗ Sep 2019 |
| Modality | Small molecule | “a novel antipseudomonal cephalosporin” NCT02070757 ↗ |
| Route | Intravenous | “Participants receive 3000 mg ceftolozane/tazobactam intravenous IV” NCT02070757 ↗ |